TTC Oncology

Executive Summary

TTC Oncology is a privately held biotech company founded in 2015 and based in San Diego, CA, dedicated to developing safer therapeutic options for metastatic breast cancer. The company holds a worldwide license from the University of Illinois Chicago covering novel compositions for therapeutic modulation of the estrogen receptor (ER) in ER+ breast cancer. TTC Oncology's approach aims to address the significant unmet need for more tolerable and effective treatments in this patient population, leveraging proprietary small molecules to modulate ER signaling. As a private entity with limited public disclosure, the company is in early stages of development, with its lead candidate likely in preclinical or early clinical phases. The company's value hinges on advancing its ER-targeting platform through regulatory milestones and generating clinical proof-of-concept data.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate50% success
• TBDPreclinical Proof-of-Concept Data Presentation60% success
• Q4 2026Series A Financing or Partnership Announcement40% success